Profile data is unavailable for this security.
About the company
Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, EryDex, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules, as well as biologics.
- Revenue in USD (TTM)0.00
- Net income in USD-30.28m
- Incorporated2012
- Employees32.00
- LocationQuince Therapeutics Inc601 Gateway Boulevard, Suite 1250SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (415) 910-5717
- Fax+1 (302) 655-5049
- Websitehttps://quincetx.com/
More ▼
Mergers & acquisitions
| Acquired company | QNCX:NSQ since announced | Transaction value |
|---|---|---|
| Erydel SpA | -42.72% | -- |
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ImmuCell Corp | 21.28m | -3.90m | 37.58m | 74.00 | -- | 1.51 | -- | 1.77 | -0.5030 | -0.5030 | 2.75 | 3.18 | 0.494 | 2.29 | 9.03 | 269,401.50 | -9.05 | -5.16 | -9.97 | -5.53 | 27.55 | 40.04 | -18.31 | -12.64 | 1.00 | -8.14 | 0.3204 | -- | -5.90 | 9.72 | -131.56 | -- | -1.39 | -- |
| NRX Pharmaceuticals Inc | 0.00 | -30.16m | 37.88m | 2.00 | -- | -- | -- | -- | -2.95 | -2.95 | 0.00 | -0.1398 | 0.00 | -- | -- | -- | -182.00 | -120.57 | -- | -168.40 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 24.14 | -- | -- | -- |
| Correlate Energy Corp | 7.56m | -12.79m | 38.20m | 19.00 | -- | -- | -- | 5.05 | -0.3554 | -0.3554 | 0.21 | -0.0877 | 2.22 | -- | 13.19 | 398,051.60 | -375.16 | -315.47 | -- | -- | 18.27 | 15.42 | -169.09 | -201.03 | -- | -0.7239 | 8.30 | -- | 122.20 | 46.12 | -78.54 | -- | -- | -- |
| Sensei Biotherapeutics Inc | 0.00 | -31.92m | 38.37m | 27.00 | -- | 0.6561 | -- | -- | -1.20 | -1.20 | 0.00 | 2.33 | 0.00 | -- | -- | 0.00 | -36.55 | -47.03 | -39.39 | -54.33 | -- | -- | -- | -- | -- | -- | 0.0241 | -- | -- | -- | 29.82 | -- | 42.16 | -- |
| Fortress Biotech Inc | 85.11m | -62.86m | 38.44m | 186.00 | -- | 1.62 | -- | 0.4516 | -6.65 | -6.65 | 7.96 | 1.19 | 0.3976 | 2.27 | 4.55 | 457,602.20 | -64.47 | -52.50 | -107.85 | -99.46 | 68.25 | 63.17 | -162.17 | -236.94 | 1.21 | -10.18 | 1.07 | -- | 11.58 | 25.75 | 27.42 | -- | -9.37 | -- |
| Quince Therapeutics Inc | 0.00 | -30.28m | 39.11m | 32.00 | -- | 0.5273 | -- | -- | -0.7599 | -0.7599 | 0.00 | 1.72 | 0.00 | -- | -- | 0.00 | -23.97 | -42.72 | -25.27 | -46.06 | -- | -- | -- | -- | -- | -- | 0.1542 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
| Unicycive Therapeutics Inc | 0.00 | -37.82m | 39.11m | 14.00 | -- | -- | -- | -- | -1.26 | -1.26 | 0.00 | 0.5779 | 0.00 | -- | -- | 0.00 | -92.81 | -218.20 | -221.58 | -609.54 | -- | -- | -- | -3,877.49 | -- | -- | 0.00 | -- | -29.02 | -- | -73.95 | -- | -- | -- |
| OncoCyte Corp | 1.38m | -40.66m | 39.16m | 43.00 | -- | 2.09 | -- | 28.33 | -4.94 | -4.94 | 0.1682 | 2.05 | 0.018 | -- | 1.34 | 32,139.54 | -51.95 | -35.11 | -58.73 | -39.71 | 22.07 | -- | -2,890.23 | -2,373.36 | -- | -157.69 | 0.00 | -- | 56.89 | -- | -34.84 | -- | 55.41 | -- |
| Incannex Healthcare Inc | 163.39k | -13.70m | 39.68m | -- | -- | 2.10 | -- | 242.87 | -0.3806 | -0.3806 | 0.0003 | 1.19 | 0.0038 | -- | 0.0554 | -- | -31.42 | -54.94 | -32.90 | -59.47 | -- | -- | -8,386.19 | -1,033.07 | -- | -- | 0.00 | -- | 61.92 | 3.38 | -24.35 | -- | 54.12 | -- |
| Medicine Man Technologies Inc | 172.45m | -42.70m | 39.95m | 729.00 | -- | 0.3165 | -- | 0.2316 | -1.60 | -1.60 | 3.01 | 1.61 | 0.5064 | 3.99 | 39.49 | 236,553.90 | -10.15 | -8.33 | -11.95 | -9.85 | 44.08 | 45.57 | -20.03 | -15.71 | 0.5027 | 0.3143 | 0.5679 | -- | 8.20 | 78.78 | -62.56 | -- | 200.89 | -- |
| Cyclo Therapeutics Inc | 1.08m | -20.06m | 40.20m | 8.00 | -- | 8.40 | -- | 37.35 | -1.33 | -1.33 | 0.0679 | 0.1666 | 0.1233 | 0.387 | 12.14 | 134,551.30 | -229.72 | -132.22 | -727.50 | -215.17 | 90.85 | 90.37 | -1,863.35 | -1,114.04 | 1.42 | -2,769.34 | 0.00 | -- | -21.76 | 1.25 | -29.81 | -- | -3.95 | -- |
| Vyne Therapeutics Inc | 423.00k | -28.50m | 40.24m | 10.00 | -- | 0.4752 | -- | 95.14 | -5.26 | -5.42 | 0.021 | 5.83 | 0.0067 | -- | -- | 42,300.00 | -44.91 | -108.41 | -50.67 | -138.57 | -- | -- | -6,738.06 | -1,907.10 | -- | -- | 0.00 | -- | -11.11 | -47.51 | 17.89 | -- | -- | -- |
| Eyenovia Inc | 3.79k | -27.26m | 40.40m | 57.00 | -- | 3.80 | -- | 10,659.02 | -0.6639 | -0.6639 | 0.00009 | 0.1976 | 0.0001 | -- | 0.0031 | 66.49 | -91.15 | -80.31 | -119.11 | -117.70 | 0.00 | -- | -719,290.30 | -680.95 | 2.16 | -15.14 | 0.6135 | -- | -- | -- | 2.68 | -- | 152.20 | -- |
| Lexaria Bioscience Corp | 404.72k | -5.44m | 40.59m | 5.00 | -- | 5.98 | -- | 100.29 | -0.6851 | -0.6851 | 0.0493 | 0.5264 | 0.0722 | -- | 1.64 | 80,944.00 | -97.62 | -95.67 | -94.18 | -96.58 | 95.66 | 76.98 | -1,351.64 | -1,612.76 | -- | -175.33 | 0.00 | -- | -11.43 | -12.19 | 8.31 | -- | -- | -- |
| Natural Alternatives International, Inc. | 120.20m | -3.31m | 40.62m | 317.00 | -- | 0.483 | 30.27 | 0.3379 | -0.5646 | -0.5646 | 20.53 | 13.56 | 0.8091 | 3.63 | 12.77 | 379,183.00 | -2.23 | 4.90 | -2.56 | 5.93 | 8.85 | 15.98 | -2.75 | 3.80 | 2.44 | -2.71 | 0.0996 | 0.00 | -9.91 | 3.06 | -76.46 | -20.74 | 27.08 | -- |
Data as of May 17 2024. Currency figures normalised to Quince Therapeutics Inc's reporting currency: US Dollar USD
15.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tang Capital Management LLCas of 31 Mar 2024 | 2.95m | 6.82% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.13m | 2.60% |
| EPIQ Capital Group LLCas of 31 Mar 2024 | 845.77k | 1.96% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 520.10k | 1.20% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 314.87k | 0.73% |
| Geode Capital Management LLCas of 31 Mar 2024 | 266.90k | 0.62% |
| Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 31 Mar 2024 | 164.75k | 0.38% |
| Bridgeway Capital Management LLCas of 31 Mar 2024 | 138.50k | 0.32% |
| Two Sigma Advisers LPas of 31 Mar 2024 | 97.10k | 0.23% |
| Susquehanna Financial Group LLLPas of 31 Mar 2024 | 96.78k | 0.22% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
